drugset / Trial / NCT02510937
Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Participation in the study will last for 3months, with a 1 month screening phase.
Timeline
- Start
- 2015-08-05
- Primary completion
- 2017-02-06
- Completion
- 2017-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC-90001 | Small molecule | 100 mg | Oral |
| Subject | CC-90001 | Small molecule | 200 mg | Oral |